Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KM-001 in PPKP1 and PC
NCT05956314Phase 1Completed
- Sponsor
- Kamari Pharma
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KM-001 in punctate palmoplantar keratoderma type 1 (PPPK1) and pachyonychia congenita (PC) (2 arms), sponsored by Kamari Pharma. Primary endpoints: Adverse Events up to 112 days, Hematology Laboratory Parameters up to 112 days and 3 more. Started Mar 2023; status: completed.
02
Drugs
KM-001
03
Conditions
punctate palmoplantar keratoderma type 1 (PPPK1)pachyonychia congenita (PC)
Beyond the preview
Go deeper on NCT05956314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956314.